Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study
暂无分享,去创建一个
Robert A. Beckman | Zoran Antonijevic | Xiaoyun Li | Cong Chen | R. Beckman | Z. Antonijevic | R. Kalamegham | Xiaoyun Li | Cong Chen | S. Yuan | Shuai Yuan | Rasika Kalamegham
[1] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[2] Baldur P Magnusson,et al. Group sequential enrichment design incorporating subgroup selection , 2013, Statistics in medicine.
[3] Robert A Beckman,et al. Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials , 2014, Clinical Cancer Research.
[4] Jan Bogaerts,et al. Designing transformative clinical trials in the cancer genome era. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Alternative Trial Designs Based on Tumor Genetics / Pathway Characteristics Instead of Histology , 2022 .
[6] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[7] Donald A Berry,et al. The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research , 2015, Molecular oncology.
[8] P. Thall,et al. Accounting for patient heterogeneity in phase II clinical trials , 2008, Statistics in medicine.
[9] Denis Lacombe,et al. The dream and reality of histology agnostic cancer clinical trials , 2014, Molecular oncology.
[10] Linda Sun,et al. Evaluation of Early Efficacy Endpoints for Proof-of-Concept Trials , 2013, Journal of biopharmaceutical statistics.
[11] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[12] Heikki Joensuu,et al. Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases , 2008, Clinical Cancer Research.
[13] L. Siu,et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Berry,et al. Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials , 2013, Clinical trials.
[15] David Wholley,et al. Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 , 2015, Clinical Cancer Research.
[16] Robert A. Beckman,et al. Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development , 2009 .
[17] Anne Whitehead,et al. Meta-Analysis of Controlled Clinical Trials , 2002 .
[18] Daniel J Sargent,et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Satrajit Roychoudhury,et al. Robust exchangeability designs for early phase clinical trials with multiple strata , 2016, Pharmaceutical statistics.
[20] R. Simon,et al. The Bayesian basket design for genomic variant-driven phase II trials. , 2016, Seminars in oncology.
[21] Christine M. Micheel,et al. Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies , 2014, Clinical Cancer Research.
[22] P. Thall,et al. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes , 2003, Statistics in medicine.
[23] R. Labianca,et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Robert A. Beckman,et al. Integrating predictive biomarkers and classifiers into oncology clinical development programmes , 2011, Nature Reviews Drug Discovery.
[25] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[26] Caroline McNeil,et al. NCI-MATCH launch highlights new trial design in precision-medicine era. , 2015, Journal of the National Cancer Institute.
[27] W. Brannath,et al. Selection and bias—Two hostile brothers , 2009, Statistics in medicine.
[28] E. C. Moseley,et al. The right drug for the right patient. , 1965, Journal of consulting psychology.